Effect of inflammation and anti-inflammatory interventions on mental health and cognitive function: A systematic review
Journal of Clinical and Basic Psychosomatics · 16.06.2026 · 025490093
DOI: 10.36922/jcbp025490093 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Clinical and Basic Psychosomatics, online erschienen am 16.06.2026. Verfasst von Sreeja Roy und 10 weiteren Autor:innen.
Abstract (Originalsprache)
Inflammation is increasingly recognized as a mechanistic pathway influencing both mental health and cognition. Elevated C-reactive protein (CRP) and interleukin-6 (IL-6) have been implicated in depressive symptom severity, treatment resistance, and impaired cognitive function. Anti-inflammatory agents, including biologics, nonsteroidal anti-inflammatory drugs (NSAIDs), statins, and adjunctive antibiotics, have been investigated in randomized controlled trials (RCTs) as potential treatments for mood and cognitive disorders. This systematic review synthesizes evidence on the association between inflammation and mental health outcomes and evaluates the efficacy of anti-inflammatory interventions. Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, PubMed, MEDLINE, Cochrane Library, PsycInfo, Embase, Scopus, and Web of Science were searched through July 30, 2024. Eligible studies were RCTs of Food and Drug Administration-approved anti-inflammatory agents reporting validated mental health or cognitive outcomes. Risk of bias was assessed using the Cochrane Risk of Bias 2.0 tool. Twenty-one RCTs met the inclusion criteria (sample sizes: 28–38,807; mean ages: 18–84 years). Elevated CRP and IL-6 predicted poor antidepressant response and accelerated cognitive decline, especially in executive and learning/memory domains (hazard ratio: 1.6, 95% confidence interval: 1.2–2.1, p = 0.004). Biologics reduced depressive symptoms in high-inflammation subgroups (CRP > 5 mg/L; mean difference on the Hamilton Depression Rating Scale: −4.2; 95% confidence interval: −6.7 to −1.8; p < 0.001). Adjunctive celecoxib improved mania scores in bipolar disorder (Young Mania Rating Scale: Δ −4.8, p = 0.02) but had inconsistent effects in depression. Statins and aspirin showed no preventive benefit for depression, with some evidence of slightly worsened symptom trajectories in older adults. Minocycline improved depressive symptoms in patients with inflammatory profiles (Montgomery– Åsberg Depression Rating Scale difference: −3.7, p = 0.01). Cognitive outcomes were rarely primary endpoints, and anti-inflammatory interventions generally showed no significant benefit on executive function, attention, or social cognition. These findings support prioritizing biomarker-stratified trials to develop precision anti-inflammatory treatments in psychiatry.
Zitieren
APA
Roy, S., Oană, B. M., Adams, G., Arvanitis, S., Ho, A., Gupta, A., Lopez, M., Clark, L., Kanbar, A., Aziz, A. A. A., & Valentino, K. (2026). Effect of inflammation and anti-inflammatory interventions on mental health and cognitive function: A systematic review. Journal of Clinical and Basic Psychosomatics, 0(0), 025490093. https://doi.org/10.36922/jcbp025490093
Vancouver
Roy S, Oană BM, Adams G, Arvanitis S, Ho A, Gupta A, et al. Effect of inflammation and anti-inflammatory interventions on mental health and cognitive function: A systematic review. Journal of Clinical and Basic Psychosomatics. 2026;0(0):025490093. doi:10.36922/jcbp025490093
BibTeX
@article{Roy2026,
author = {Roy, Sreeja and Oană, Bianca M. and Adams, Grace and Arvanitis, Sofia and Ho, Alena and Gupta, Anirudh and Lopez, Megan and Clark, Lexi and Kanbar, Amir and Aziz, Areej Abdul Aziz and Valentino, Kyle},
title = {Effect of inflammation and anti-inflammatory interventions on mental health and cognitive function: A systematic review},
journal = {Journal of Clinical and Basic Psychosomatics},
year = {2026},
volume = {0},
number = {0},
pages = {025490093},
doi = {10.36922/jcbp025490093}
}
EUVIMED